An observational study in Persistent Pulmonary Hypertension of Newborn, sponsored by Ferrer Internacional S.A.. Recruiting at 4 sites in France. Open to participants aged Up to 44 Weeks. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Ferrer Internacional S.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This observational study will seek to describe the uses and safety and efficacy outcomes of treprostinil in clinical practice in patients with persistent pulmonary hypertension (PPHN).
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
This study's planned enrollment of 60 is below the median of 125 across 12 observational studies indexed under Persistent Fetal Circulation Syndrome.
Browse Persistent Fetal Circulation Syndrome studies →Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Approximately 60 newborns with PH (of whom at least 40 newborns with persistent pulmonary hypertension of the newborn [PPHN]) are expected to be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Characteristics of neonates receiving treprostinil in the clinical practice.
Sex (male/female) ; Gestational Age (weeks) ; Birth Weight (g) ; Apgar (1 and 5 min, 0-10) and Time from birth to treprostinil initiation (h)
Time frame: From baseline to Day 30 after last dose of treprostinil
Treprostinil-specific treatment patterns.
Prior concomitant treatments, treprostinil route, treprostinil dose(s) (mg/ml) and treprostinil treatment duration (days).
Time frame: From baseline to Day 30 after last dose of treprostinil
Number of participants with treatment-related adverse events to evaluate safety.
Time frame: From baseline to Day 30 after last dose of treprostinil
Composite endpoint of absence of complications through Day 14 after the index date.
Time frame: From baseline to Day 30 after last dose of treprostinil
Description of the clinical outcomes from treprostinil start day (i.e., Day 0) to Day 14 and at Day 30 after last dose of treprostinil.
Evolution of pre- and post-ductal oxygen saturation (SpO2); oxygen partial pressure (PO2); clinical laboratory parameters and fraction of inspired oxygen (FiO2) at times 0h, 24h, 48h, 72h, Day 7, Day 14, and Day 30 after last dose of treprostinil.
Time frame: 0h, 24h, 48h, 72h, Day 7, Day 14, and Day 30 after last dose of treprostinil (if applicable).
Description of neurodevelopmental progress over 2 years after treprostinil initiation through a Global Clinical Impression Scale.
Time frame: From day 30 after treprostinil treatment to Year 2 after last dose of treprostinil
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Persistent Fetal Circulation Syndrome →